Free Trial

Pfizer (PFE) Competitors

$28.58
-0.22 (-0.76%)
(As of 06/7/2024 ET)

PFE vs. JNJ, MRK, ABBV, BMY, ZTS, RPRX, JAZZ, PRGO, CORT, and SUPN

Should you be buying Pfizer stock or one of its competitors? The main competitors of Pfizer include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.

Pfizer vs.

Johnson & Johnson (NYSE:JNJ) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.

Johnson & Johnson has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Pfizer received 403 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.06% of users gave Pfizer an outperform vote while only 64.95% of users gave Johnson & Johnson an outperform vote.

CompanyUnderperformOutperform
Johnson & JohnsonOutperform Votes
1086
64.95%
Underperform Votes
586
35.05%
PfizerOutperform Votes
1489
69.06%
Underperform Votes
667
30.94%

69.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 0.2% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Johnson & Johnson pays an annual dividend of $4.96 per share and has a dividend yield of 3.4%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Johnson & Johnson pays out 30.9% of its earnings in the form of a dividend. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 1 consecutive years and Pfizer has increased its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

Johnson & Johnson has higher revenue and earnings than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$85.16B4.16$35.15B$16.049.17
Pfizer$58.50B2.77$2.12B-$0.06-476.25

Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of -0.56%. Pfizer's return on equity of 36.70% beat Johnson & Johnson's return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson45.26% 36.70% 15.07%
Pfizer -0.56%8.64%3.70%

Johnson & Johnson presently has a consensus price target of $174.07, suggesting a potential upside of 18.35%. Pfizer has a consensus price target of $35.86, suggesting a potential upside of 25.46%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, analysts plainly believe Pfizer is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
8 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.38
Pfizer
0 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Pfizer had 6 more articles in the media than Johnson & Johnson. MarketBeat recorded 34 mentions for Pfizer and 28 mentions for Johnson & Johnson. Pfizer's average media sentiment score of 0.71 beat Johnson & Johnson's score of 0.65 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
16 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
21 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Johnson & Johnson beats Pfizer on 11 of the 20 factors compared between the two stocks.

Get Pfizer News Delivered to You Automatically

Sign up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PFE vs. The Competition

MetricPfizerPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$161.95B$6.97B$5.21B$17.72B
Dividend Yield5.83%2.66%2.73%3.55%
P/E Ratio-476.2510.86119.1222.92
Price / Sales2.77244.022,422.7414.39
Price / Cash9.6832.9335.1220.21
Price / Book1.815.654.964.99
Net Income$2.12B$147.15M$110.41M$975.94M
7 Day Performance-0.28%-2.06%-1.08%-1.87%
1 Month Performance1.08%-2.38%-0.64%-0.74%
1 Year Performance-26.89%-5.74%2.85%8.66%

Pfizer Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JNJ
Johnson & Johnson
4.6379 of 5 stars
$147.80
+0.0%
$174.07
+17.8%
-7.2%$355.71B$85.16B9.21131,900Analyst Forecast
MRK
Merck & Co., Inc.
3.9065 of 5 stars
$128.69
+0.2%
$131.33
+2.1%
+20.3%$325.95B$60.12B142.9972,000Analyst Forecast
ABBV
AbbVie
4.6156 of 5 stars
$162.16
+1.2%
$176.14
+8.6%
+24.1%$286.35B$54.32B48.1250,000Analyst Upgrade
BMY
Bristol-Myers Squibb
4.9331 of 5 stars
$41.76
0.0%
$60.00
+43.7%
-36.3%$84.64B$45.01B-13.4734,100
ZTS
Zoetis
4.7271 of 5 stars
$171.88
-0.3%
$211.75
+23.2%
+8.1%$78.43B$8.54B33.1214,100
RPRX
Royalty Pharma
4.8555 of 5 stars
$27.02
+0.7%
$43.00
+59.1%
-18.7%$16.14B$2.36B20.1651Positive News
JAZZ
Jazz Pharmaceuticals
4.9724 of 5 stars
$104.48
-1.2%
$192.75
+84.5%
-12.8%$6.59B$3.83B21.542,800Analyst Forecast
PRGO
Perrigo
4.9715 of 5 stars
$27.18
-1.7%
$40.67
+49.6%
-20.1%$3.71B$4.66B-388.299,140Positive News
CORT
Corcept Therapeutics
4.7966 of 5 stars
$32.87
+5.0%
$44.30
+34.8%
+39.5%$3.42B$482.38M31.01352Analyst Forecast
Insider Selling
News Coverage
SUPN
Supernus Pharmaceuticals
3.9442 of 5 stars
$27.92
+1.1%
$41.00
+46.8%
-25.9%$1.53B$607.52M-96.28652Positive News

Related Companies and Tools

This page (NYSE:PFE) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners